{"id":1915,"date":"2020-06-18T15:20:01","date_gmt":"2020-06-18T02:20:01","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=1915"},"modified":"2020-06-18T15:20:01","modified_gmt":"2020-06-18T02:20:01","slug":"https-www-medscape-com-viewarticle-932340","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=1915","title":{"rendered":"Three-Drug Combo Promising Against High-Risk CLL"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243;]<\/p>\n<h1 class=\"title\">Three-Drug Combo Promising Against High-Risk CLL<\/h1>\n<p>[\/vc_custom_heading][vc_column_text]For patients with high-risk\u00a0<a class=\"cl_ref_article_199313\" href=\"https:\/\/emedicine.medscape.com\/article\/199313-overview\">chronic lymphocytic leukemia<\/a>\u00a0(CLL), first-line therapy with a triple combination of targeted agents showed encouraging response rates in the phase 2\u00a0<a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02758665?term=obinutuzumab+venetoclax+ibrutinib+cll+deletion+17p&amp;draw=2&amp;rank=1\" target=\"_blank\" rel=\"noopener noreferrer\">CLL2-GIVe trial<\/a>.<\/p>\n<p>Among 41 patients with untreated CLL bearing deleterious TP53 mutations and\/or the 17p chromosomal deletion who received the GIVe regimen consisting of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta), the complete response rate at final restaging was 58. 5%, and 33 patients with a confirmed response were negative for minimal residual disease after a median follow-up of 18<\/p>\n<p><a href=\"https:\/\/www.medscape.com\/viewarticle\/932340\">To continue reading click here.<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>For patients with high-risk chronic lymphocytic leukemia (CLL), first-line therapy with a triple combination of targeted agents showed encouraging response rates in the phase 2 CLL2-GIVe trial.<\/p>\n","protected":false},"author":1,"featured_media":941,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[12],"tags":[],"class_list":["post-1915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/12\/unnamed.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/1915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1915"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/1915\/revisions"}],"predecessor-version":[{"id":1916,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/1915\/revisions\/1916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/941"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}